Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Risk and Prevention / Genetics & Family History
Posting Date: 03/23/2012This article provides an introduction to several of the more common genetic mutations associated with cancer risk and development.
The most common cause of hereditary breast cancer is an inherited mutation in the BRCA1 or BRCA2 gene. If you have inherited a mutated copy of either gene from a parent, you have an estimated 40-85% chance of developing breast cancer during your lifetime. People with these mutations tend develop cancer at a younger age (before age 40) and cancers more often affect both breasts. People with these inherited mutations also have an increased risk for developing other cancers, particularly ovarian cancer, but also male breast cancer, pancreatic cancer, and prostate cancer. BRCA mutations occur more commonly in individuals of Ashkenazi Jewish (Eastern European) decent, Norwegian, Dutch, and Icelandic populations, but they can occur in any racial or ethnic group.
If you know that you have a BRCA 1 or BRCA2 mutation, you should talk to a healthcare provider to ensure you receive the proper screening or treatment (chemoprevention) to reduce the chance of developing cancer or to detect cancer at an earlier stage when treatment is most effective. Your healthcare provider may recommend getting mammograms at a younger age, special breast and/or ovarian cancer screening tests, or other interventions, such as, prophylactic (preventative) surgery or chemoprevention.
Learn more about BRCA mutations and cancer risk Breast Cancer.org, the National Cancer Institute, Memorial Sloan Kettering CC and FORCE.
Hereditary Non-Polyposis Colon Cancer (HNPCC)
HNPCC, also known as Lynch syndrome, is caused by an inherited mutation in any one of several genes that help to repair DNA damage. About 3 to 5 % of all colorectal cancers occur in people with HNPCC, with most of these cancers occurring before the age of 50. The lifetime risk of colorectal is estimated to be as high as 80% in people with HNPCC.
People with HNPCC may develop polyps at the same rate as others, but these polyps are more likely to become cancer and in a shorter period of time. It is important that people with HNPCC begin having colonoscopies at age 20-25 and that colonoscopy is repeated every 1-2 years because cancer can occur so early and quickly in this population.
Women with HNPCC also have a very high risk of developing cancer of the endometrium (lining of the uterus). The estimated lifetime risk for endometrial cancer in these women is 40-60% and the average age at diagnosis is 50 years old. It is recommended that women with HNPCC have an annual transvaginal ultrasound or endometrial biopsy starting at age 25-35. Other cancers linked with HNPCC include cancer of the breast, ovary, stomach, small bowel, pancreas, kidney, brain, ureters (tubes that carry urine from the kidneys to the bladder), and bile duct.
Learn more about HNPCC and colon cancer on OncoLink, the National Cancer Institute, Memorial Sloan Kettering CC and Mt. Sinai Hospital.
FAP is caused by a mutation in the APC gene, which is most often inherited from a parent. In 30% of cases, however, it occurs without a family history. About 1% of all colorectal cancers are diagnosed in people with FAP. People with FAP typically develop hundreds or thousands of polyps in their colon and rectum, beginning in their teens or early adulthood, some as early as 10 years old. Cancer usually develops in 1 or more of these polyps as early as age 20. By age 40, almost all people with FAP will have developed colorectal cancer if preventive colectomy (surgery to remove the colon) is not done. For this reason, most physicians recommend colectomy at a young age for cancer prevention in individuals with FAP. Several other cancers are associated with FAP, including periampullary (where the bile duct and pancreas empty into small intestine) and thyroid cancer.
Learn more about FAP and colorectal cancer on OncoLink, the National Library of Medicine and Mt. Sinai Hospital.
Dr. Tobey discusses some of the controversy surrounding breast cancer screening with mammography. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

